Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.
Hypertension is a frequent complication in diabetes, and microalbuminuria has become an essential index of cardiovascular prognosis in type 2 diabetics. The pilot study reported here shows that rilmenidine, in addition to its antihypertensive action and good clinical tolerability, has the further advantage of reducing microalbuminuria, similar to captopril.
Hôpital Bégin, St. Mandé, France.
O
O
Dupuy
B
B
Bauduceau
H
H
Mayaudon
D000959:Antihypertensive Agents / Q000378:metabolism* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D054755:Imidazoline Receptors; D010080:Oxazoles / Q000378:metabolism* / Q000627:therapeutic use*; D011955:Receptors, Drug / Q000378:metabolism*; D000077769:Rilmenidine
D000959:Antihypertensive Agents; D054755:Imidazoline Receptors; D010080:Oxazoles; D011955:Receptors, Drug; C410887:imidazoline I1 receptors; D000077769:Rilmenidine